Global Health Leaders Mobilize Funding to Revive Andes Virus Vaccine Research

Following the international deployment linked to the MV Hondius cluster, a coalition of global health organizations and medical research funds have announced an emergency mobilization of grants targeting hantavirus preventative treatments. Scientific teams highlighted that promising virus-like particle (VLP) vaccine candidates and monoclonal antibody therapies, which had previously demonstrated strong efficacy in early-stage laboratory models in South America, had been put on hold due to a long-term lack of commercial and public sector funding. The new international consortium aims to reactivate these clinical trial pipelines immediately. The World Health Organization (WHO) welcomed the financial commitment, noting that while the current cluster is heavily contained with case metrics firmly locked at 11, establishing a robust vaccine framework is vital for preventing future high-mortality outbreaks of the Andes strain. Epidemiological data remains stable across all 12 monitored nations, with zero new secondary infections reported over the last 24 hours.